Safety of sequential immune checkpoint inhibitors after prior immune therapy

BACKGROUND: The use of immune checkpoint inhibitors (ICI) has transformed cancer treatment. Subsequent ICI use has become increasingly common following disease progression. We aim to evaluate the safety and tolerability of the sequential ICI treatment modality. METHODS: Retrospective review of confi...

Descripción completa

Detalles Bibliográficos
Autores principales: Awidi, Muhammad, Connell, Brendan, Johnson, Delaney, Craven, Isabel, Ranjit, Rojer, Gil, Brigitte, Dal’Bo, Natalie, Maher, Lewena, Daves, Seanna Reilly, McDonald, Stephanie, Gunturu, Krishna S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129922/
https://www.ncbi.nlm.nih.gov/pubmed/35727369
http://dx.doi.org/10.1007/s00432-022-04137-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129922/
https://www.ncbi.nlm.nih.gov/pubmed/35727369
http://dx.doi.org/10.1007/s00432-022-04137-4

Ejemplares similares